| Invested through |
|
|---|---|
| Asset Classes | Listed equity & Corporate bonds |
| Impact strategy | Impact Equities and Bonds |
| Bloomberg ticker | NOVOB DC |
| ISIN code | DK0062498333 |
| Industry group | Pharmaceuticals, Biotechnology & Life Sciences |
| Aligned with SDGs |
Novo Nordisk is a healthcare company that discovers, develops, manufactures and distributes pharmaceutical products worldwide. It operates through two segments. The diabetes and obesity care segment represents more than 85% of sales and offers insulin and related products, glucagon-like peptide-1 (GLP-1) and related delivery systems, oral antidiabetic products (OAD), and medicines for obesity and other serious chronic diseases. The Biopharm segment covers treatments for rare blood disorders such as haemophilia, rare endocrine disorders, growth disorders, hormone replacement therapy and other serious chronic diseases, which is currently focused on cardiovascular diseases, NASH and chronic kidney disease. The company’s biggest markets are North America, accounting for almost half of total revenues and EMEA with a bit more than one quarter of total revenues. The remainder is spread over different geographic regions. The company was founded in 1925 in Denmark as an insulin producer and is headquartered in Bagsværd, Denmark.
Investment rationale
Novo Nordisk’s largest segment is focused on treatments for diabetes, a chronic disease which leads to serious damage to the heart, blood vessels, eyes, kidneys, and nerves if untreated. Over 422 million or 8.5% of adults globally suffer from diabetes and diabetes has been the direct cause of 1.5 million deaths in 2019 (WHO), making its treatment important to achieve global health. Novo Nordisk is a significant player in treatment for diabetes.
Another serious chronic disease that afflicts a high share of the population worldwide is obesity, which is closely linked to type 2 diabetes and poses a range of other health risks like cancer and heart disease. Novo Nordisk has worked on getting the disease widely recognized as such and to offer medical treatment to help effective management of it. The company’s products further address haemophilia, growth disorders and hormone replacement therapy.
In addition, the company has an equitable pricing strategy for recombinant human insulins for all least developed countries and some low- and middle-income countries with large low-income populations. Two of Novo Nordisk's treatments are considered essential medicines by the WHO.
Alignment with Triodos Transitions:
100% of company revenues is aligned with the Wellbeing Transition. The contribution to the Wellbeing Transition comes from 100% of revenues related to the impact objective Health Care.